- Reuters•3 hours ago
Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition. The two companies said on Monday that the U.S. Food and Drug Administration had accepted dupilumab for priority review for treating atopic dermatitis (AD), a skin inflammation also known as atopic eczema, and set a target decision date of March 29. Dupilumab, an injectable antibody drug, is seen by investors as perhaps Sanofi's most promising pipeline medicine, since it has produced promising clinical results and could be first systemic therapy for severe AD.
- GlobeNewswire•6 hours agoSanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA Paris, France, and Tarrytown, N.Y. - September 26 , 2016 - Sanofi and Regeneron Pharmaceuticals, ...
- PR Newswire•6 hours agoRegeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
TARRYTOWN, N.Y. and PARIS, Sept. 26, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), a serious, chronic inflammatory skin disease. To access this call, dial (888) 771-4371 (U.S.), 0805 102 604 (France), or 0808 238 9578 (UK). The conference call will include a presentation followed by a Q&A session.
Paris - Paris Delayed Price. Currency in EUR
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||67.39 - 68.17|
|52wk Range||24.83 - 93.82|
|1y Target Est||N/A|
|P/E Ratio (ttm)||21.04|
|Avg Vol (3m)||9,830|
|Dividend & Yield||N/A (N/A)|